PDUFA dates January 2024: FDA calendar and catalysts.
0 PDUFA dates fell in January 2024. The FDA calendar also recorded 39 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in January 2024
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
January 2024: other FDA decisions and filings
January 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jan 2024Month disclosed | lepzacitinib (ATI-1777) | ACRS | Topline readout | mild to severe atopic dermatitis | Positive | SEC Form 10-Q |
| Jan 2024Month disclosed | — | ALVO | Topline readout | — | Positive | SEC Form 10-K |
| Jan 2024Month disclosed | Eylea® | ALVO | Topline readout | neovascular | Positive | SEC 8-K Exhibit 99.1 |
| Jan 2024Month disclosed | PAVBLU® (aflibercept) | ALVO | Topline readout | neovascular | Positive | SEC 8-K Exhibit 99.1 |
| Jan 2024Month disclosed | JAKAFI (ruxolitinib) | INCY | Topline readout | — | Positive | SEC Form 10-Q |
| Jan 2024Month disclosed | ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide (IHL-42X) | IXHL | Topline readout | — | Positive | SEC Form 10-Q |
| Jan 2024Month disclosed | urcosimod (OK-101) | OKYO | Topline readout | DED patients | Positive | SEC 8-K Exhibit 99.1 |
| Jan 2024Month disclosed | denifanstat (TVB-2640) | SGMT | Topline readout | — | Positive | sec_424b |
| January 8, 2024 | HLP004 | HELP | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| January 8, 2024 | CYB004 | HELP | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
January 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jan 2024Month disclosed | KANJINTI® (trastuzumab) | BNTX | Trial start | HER2-expressing advanced solid tumors | Completed | SEC 8-K Exhibit 99.1 |
| Jan 2024Month disclosed | onvuzosiran | ADRX | Trial start | — | Completed | sec_424b |
| Jan 2024Month disclosed | ELI-002 | ELTX | Trial start | — | Completed | SEC Form 10-K |
| Jan 2024Month disclosed | Tagrisso® (osimertinib) | GNPX | Trial start | — | Completed | SEC Form 8-K |
| Jan 2024Month disclosed | chikungunya (VLA1553) | VALN | Trial start | — | Completed | SEC Form 10-K |
| Jan 2024Month disclosed | IXCHIQ | VALN | Trial start | — | Completed | SEC Form 10-K |
| Jan 2024Month disclosed | FT825 | FATE | Trial start | advanced solid tumors | Completed | SEC Form 10-K |
| Jan 2024Month disclosed | Tecentriq® (atezolizumab) | GNPX | Trial start | — | Completed | SEC Form 10-Q |
| Jan 2024Month disclosed | OP-3136 | OLMA | Trial start | ER+/HER2- metastatic breast cancer and other cancers | Completed | SEC Form 10-K |
| Jan 2024Month disclosed | nomlabofusp (CTI-1601) | LRMR | Trial start | — | Completed | SEC Form 10-Q |
| Jan 2024Month disclosed | VBP301 | VOR | Trial start | — | Completed | SEC Form 10-K |
2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps January 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in January 2024?
0 PDUFA dates fell in January 2024. The FDA calendar also recorded 39 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.